Brief: Valneva Announces Positive Immunogenicity And Safety Data For Lyme Vaccine
03/09/2025 06:05
Sept 3 (Reuters) - Valneva SE VLS.PA: ANNOUNCES POSITIVE IMMUNOGENICITY AND SAFETY DATA FOR LYME VACCINE VLA15-221 PHASE 2 STUDY SHOWS SIGNIFICANT ANTIBODY RESPONSE ACROSS SEROTYPES PFIZER AIMS TO SUBMIT BLA TO FDA AND MAA TO EMA IN 2026 Source text: ID:nGNEMQZj5 Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48587696600;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency